305 related articles for article (PubMed ID: 25016809)
1. [Novel targeted therapy in multiple myeloma].
Izumi T
Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
3. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
6. Novel generation of agents with proven clinical activity in multiple myeloma.
Mateos MV; Ocio EM; San Miguel JF
Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
8. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
10. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
11. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
12. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
14. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
15. Sequential or combination therapy for multiple myeloma.
Nooka A; Lonial S
Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
[TBL] [Abstract][Full Text] [Related]
16. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
17. Future directions in immunomodulatory therapy.
Lonial S
Med Oncol; 2010 Jun; 27 Suppl 1():S62-6. PubMed ID: 20012563
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in CNS myeloma treatment.
Gozzetti A; Cerase A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):23-7. PubMed ID: 25134940
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy of multiple myeloma: the new generation drugs.
Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
[TBL] [Abstract][Full Text] [Related]
20. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]